Member Info for B_Positive

PREM had a 300% in a week rise with no news from a 5mil cap with 50bil shares in issue with 60mil in debt and no funds.

This from a 1mil cap with only 1bil shares and funded for 2025 with gold at $3000+ can do more than 300% in a week I feel.

This is both the next VAST and PREM.

A beaten down dog about to move up several hundred percent from its low point and barking loudly once more.

2p this week won't be difficult to hit as the mcap remains so little even at that level and then once cleared it goes a lot higher.

Excellent.

The board at GDR seem more confident than I can remember for many years.

What have they got cooking?

Absolutely. This company in the space its operating is worth considerably more than it is currently priced at.

Let the good times and good news roll in.

291,525 bought this morning at 1.14p and just sold for a notable loss at 1.02p LOL

Which mupper was that? Own up.

This will head to 3p from this market cap.

£12m cap is just 3p.

Absolutely nothing for a massive longevity research companies which has secured 12m euros grant funding already and now has AI embedded.

The fumes of the placing creating and opportunity here. Once it goes I expect this to be trading around 5p again this quarter.

It's going to be news rich and recent news deserves a rereate here

Yes, it does read well for GDRs fortunes this year

Absolutely Jimi

The recent RNS have been very clear.

2025 is set to be a significant and strong year for GDR, much much stronger than 2024 where it moved 300% up on nothing.

Thus I am more bullish for GDR's fortunes in 2025 compared to 2024 and think it will move up harder and higher once it gets going.

Gimme more at 1p baby. No gap up please MMs.

April, May and June this always see's the big EU grant cash too.

Https://www.lse.co.uk/rns/GDR/additional-grant-funding-under-devote-programme-2vhxtl0zvqt4mzf.html

https://www.lse.co.uk/rns/GDR/c16312m-grant-awarded-au2dg2yonvbudim.html

https://www.lse.co.uk/rns/GDR/multi-partner-grant-awarded-dq7dmm2kvxi048u.html

Another great thing about GDR is it has a history of securing huge dillutive free grant cash as well.

Anyway we can see the company is funded for 2025, so worry about that in 7-9 months time and for now live in the present and focus what's in front of you. A huge newsflow rich period.

End of March cash = £1m

Raise + £1m

Open offer + £225k

Tax reciept + £500k

Grant + £200k minimum

Therefore cash is healthy at around £3m.

Then consider

+growing revenues

+reducing costs

+further new contracts anticipated

+expansion of exisiting contracts

+interntional market entry

+new UK partnerships

+new US partnerships

We can see the company is geared for profitability and is funded well for the remainder of this year and well into 2026.

Dyor of course.

Welcome to AIM none of these companies are profitable but we love them deep within our hearts anyway

Next comes the massive grant money.

With the IPO at 8p and all time highs of 12p this has a long recovery ahead

Or equally there will be several contracts and big developments as suggested are looming in the recent RNS

· Distributors contracted in key international geographies, with site installations in Italy and Saudi Arabia and additional sites expected near-term

· Accepted on NHS Dynamic Procurement System (DPS), permitting direct procurement by regional NHS trusts

· Breakthrough Device Designation received from the FDA. Progressing as planned, with first-engagement with FDA under programme initiated

Genedrive

· Expansion of operational capabilities; onshoring and increased production pipeline of instrumentation, with internalisation of MT-RNR1 and CYP2C19 assay manufacturing to be dual-source supply and complement external vendors scaled-up production capabilities

· Growing base of post-implementation phase "routine clinical user" sites which in turn lead to recurring revenue source for both tests

· Expansion of sales and marketing team, in-country distributors and in-country market access facilitation

· Product Development: focus on on-market product support of CYP2C19 and MT-RNR1, with routine product improvements to further facilitate ease of implementation and usability

I believe the company can get there with its products, accreditaitons and gradual intergration into the NHS and global health systems.

Genedrive® CYP2C19

· First UK commercial sales of the Genedrive® CYP2C19-ID Kit to England's largest Hyperacute Stroke Centre

· North West Anglia Foundation NHS Trusts' Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use

· Growing base of initial installations for site verifications expected to lead to subsequent routine clinical use

· Positive value assessment by the Scottish Health Technologies Group (SHTG) following referral by the Accelerated National Adoption (ANIA) pathway group in Scotland, leading to the Scottish Government announcement of investment to support national pharmacogenetic testing of CYP2C19 in Stroke patients, including genedrive's CYP2C19-ID test for rapid genetic testing in Transient Ischaemic Attack (TIA) patients

· NICE recommendation of the Genedrive® CYP2C19-ID Kit as the rapid genetic testing platform of choice for CYP2C19 genotyping strategies for clopidogrel administration in ischaemic stroke (IS) and TIA, with Genedrive's CYP2C19 ID Kit being dominant in cost effectiveness models

· Genedrive® CYP2C19-ID Kit clinical performance published in Journal of Molecular Diagnostics (December 2024), outlining superior performance to laboratory test and alternative available point of care (PoC) platforms with respect to target coverage, speed, accuracy and test fails

· Inclusion in study aimed at understanding how best to deliver CYP2C19 based genotyping at scale throughout the NHS, and accepted on NHS Dynamic Procurement System (DPS), permitting direct procurement by regional NHS trusts

· Market access routes and reimbursement strategies defined in key initial international target countries, including the Middle East region, with well-positioned and aligned in-country distributors, with required regulatory certification (CE-IVD under IVDR) on track for April 2025

· 510(k) route identified for regulatory submission for US market entry, with initial pre-submission engagement with Food and Drug Administration (FDA) held and feedback positive and with regulatory approach confirmed as appropriate

Genedrive® MT-RNR1

· Scottish Government announcement of £800k investment to support national phased implementation program of pharmacogenetic testing of MT-RNR1 in newborn babies in NHS Scotland using Genedrive's MT-RNR1 ID Kit

· NIHR and OLS Funding Package of c.£500k to address NICE Real World Evidence Generation Requirements for the Genedrive® MT-RNR1 ID Kit across 14 hospitals across the UK (PALOH-UK). Progressing as planned, with nine Group 1 sites live, with a further five Group 2 sites phased to go-live from May 2025

· 11 babies identified as positive for the MT-RNR1 DNA variant since introduction of the test into Neonatal Intensive Care Units (NICU) in the UK and avoiding lifelong hearing loss

The debt free stock with 24months cash with Farnell and Schurter backing LOL

I can give you 100 other AIM stocks which will go bust this year if you want to waste your life on those boards writing incorrect post after incorrect post

I think all the fundamentals are there for such a move and overall CPX offers a more compelling investment case than most of the penny stocks we know.

Well just remember 1/6th of last years placing = 1/6th of the churn so it won't be long.

Even with a 6x larger placing last year it did 300% with pretty weak news which speaks volumes about how much the retail loves this stock.

So this year I wouldn't rule out 3,000% when weighing it all up.